Ligand validation:6W8I

TKY: 14-{[(3S)-2-(N-methyl-L-alanyl-3-methyl-L-valyl)-3-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl}-1,2,3,4-tetrahydroisoquinolin-7-yl]oxy}-3,6,9,12-tetraoxatetradecan-1-yl (3R)-3-{5-amino-4-carbamoyl-3-[4-(2,4-difluorophenoxy)phenyl]-1H-pyrazol-1-yl}piperidine-1-carboxylate

TKY is a Ligand Of Interest in 6W8I designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6W8I_TKY_D_502	12%	67%	0.368	0.906	0.52	0.74	3	3	0	0	100%	1
6W8I_TKY_E_502	11%	68%	0.375	0.899	0.51	0.72	2	3	0	0	100%	1
6W8I_TKY_C_701	6%	66%	0.443	0.876	0.53	0.78	2	4	0	0	100%	1
6W74_TKY_A_402	13%	71%	0.202	0.837	0.3	0.82	-	2	0	0	46%	0.4588

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.